Literature DB >> 10194165

Effect of nitric oxide on rhinovirus replication and virus-induced interleukin-8 elaboration.

P Kaul1, I Singh, R B Turner.   

Abstract

Nitric oxide (NO) has been reported to have disparate effects in different viral infections. We conducted a study to determine whether rhinovirus (RV) infection is associated with production of NO, and to assess the effect of NO on RV-induced interleukin-8 (IL-8) elaboration both in vitro in monolayers of BEAS-2B cells, an immortalized respiratory epithelial cell line, and in MRC-5 cells, a diploid human embryonic lung fibroblast cell line, challenged with purified RV type 39, as well as in vivo, in experimental infections with RV type 23. Virus replication was not affected by pretreatment of cell monolayers with any of three different NO donors, and RV infection did not stimulate production of NO. Pretreatment of cell monolayers with either NO donors or inhibitors of NO synthase had no effect on RV-induced IL-8 elaboration measured either 6 or 24 h after virus challenge. Nasal wash specimens from RV-infected volunteers contained low concentrations of nitrite that were not different from the concentrations in specimens from sham-challenged subjects. The concentration of nitrite in these specimens did not change over the course of the subjects' rhinoviral illness. These results suggest that NO does not participate in the pathogenesis of RV infections.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10194165     DOI: 10.1164/ajrccm.159.4.9808043

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  12 in total

1.  Nerve growth factor modulates human rhinovirus infection in airway epithelial cells by controlling ICAM-1 expression.

Authors:  Sreekumar Othumpangat; Michael Regier; Giovanni Piedimonte
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-03-16       Impact factor: 5.464

Review 2.  Viral rhinitis.

Authors:  D A Gentile; D P Skoner
Journal:  Curr Allergy Asthma Rep       Date:  2001-05       Impact factor: 4.806

Review 3.  Respiratory syncytial virus infections in the adult asthmatic--mechanisms of host susceptibility and viral subversion.

Authors:  Blair D Westerly; R Stokes Peebles
Journal:  Immunol Allergy Clin North Am       Date:  2010-09-22       Impact factor: 3.479

Review 4.  Rhinoviruses in the pathogenesis of asthma.

Authors:  Nikolaos G Papadopoulos; Stelios Psarras
Journal:  Curr Allergy Asthma Rep       Date:  2003-03       Impact factor: 4.919

5.  Could nasal nitric oxide help to mitigate the severity of COVID-19?

Authors:  Jan Martel; Yun-Fei Ko; John D Young; David M Ojcius
Journal:  Microbes Infect       Date:  2020-05-06       Impact factor: 2.700

Review 6.  The treatment of rhinovirus infections: progress and potential.

Authors:  R B Turner
Journal:  Antiviral Res       Date:  2001-01       Impact factor: 5.970

7.  Rhinovirus-induced oxidative stress and interleukin-8 elaboration involves p47-phox but is independent of attachment to intercellular adhesion molecule-1 and viral replication.

Authors:  P Kaul; M C Biagioli; I Singh; R B Turner
Journal:  J Infect Dis       Date:  2000-06-05       Impact factor: 5.226

Review 8.  The role of respiratory viruses in acute and chronic asthma.

Authors:  A Tuffaha; J E Gern; R F Lemanske
Journal:  Clin Chest Med       Date:  2000-06       Impact factor: 2.878

9.  Assessment of airflow limitation, airway inflammation, and symptoms during virus-induced wheezing episodes in 4- to 6-year-old children.

Authors:  George N Konstantinou; Paraskevi Xepapadaki; Emmanuel Manousakis; Heidi Makrinioti; Kalliopi Kouloufakou-Gratsia; Photini Saxoni-Papageorgiou; Nikolaos G Papadopoulos
Journal:  J Allergy Clin Immunol       Date:  2012-11-27       Impact factor: 10.793

Review 10.  The human rhinovirus: human-pathological impact, mechanisms of antirhinoviral agents, and strategies for their discovery.

Authors:  Judith M Rollinger; Michaela Schmidtke
Journal:  Med Res Rev       Date:  2011-01       Impact factor: 12.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.